Menu Search
Equities

Biocure Technology Inc

1WH:FRA

Biocure Technology Inc

Actions
  • Price (EUR)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change-98.04%
  • Beta--
Data delayed at least 15 minutes, as of Sep 14 2023 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biocure Technology Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In addition, the Company is developing Biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD3.04m
  • Incorporated2007
  • Employees--
  • Location
    Biocure Technology Inc300-1055 West Hastings StreetVANCOUVER V6E 2E9CanadaCAN
  • Phone+1 (604) 609-7149
  • Fax+1 (604) 609-7149
  • Websitehttps://biocuretech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		 since
announced		Transaction
value
Atriva Therapeutics GmbHAnnounced18 Sep 202318 Sep 2023Announced50.00%--
Data delayed at least 15 minutes, as of Sep 11 2023.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.